Disease progression pattern in metastatic breast cancer patients treated with anti-HER2 therapies

D. Serpico, L. Porcu, A. Tessari, A. Gevorgyan, G. Bregni, G. Galli, F. de Braud, V. Torri, S. Di Cosimo

Research output: Contribution to journalArticle

Abstract

Purpose: Over the last decade a dramatic improvement in the treatment and prognosis of human epidermal growth factor receptor-2 (HER2) positive metastatic breast cancer (MBC) has been achieved. This study aimed to describe pattern, timing of metastases, and time to progression (TTP) of MBC patients (pts) treated with multiple lines of therapy with trastuzumab and/or lapatinib. Methods: Clinical-pathologic features, treatment-lines and metastatic sites were collected from the institutional database; TTP was evaluated for each treatment-line. A meta-analysis of treatment-line estimates was performed; Q test and I2-index were used to detect and estimate heterogeneity. Cox’s proportional hazards model and Fine and Gray’s proportional subhazards model in a competing risks setting were used to detect differences in hazard rate and to estimate relative risks. Results: 112 pts were analyzed. The median number of treatment-lines administered was 6 (range 1–17) and 524 (86 %) disease progression events were observed (median follow up 4.2 years). Distribution of metastases at baseline remained consistent across all lines. Having a given site affected by metastasis was a major risk factor of progression in that site. Hormone-receptor-positive pts resulted more likely to progress on bone (HR = 1.88). Elderly pts were less likely to progress on CNS (HR = 0.73). Median TTP resulted superior to 5 months up to the 6th line of treatment, reaching a plateau at the 9th treatment-line. Conclusions: These data suggest that risk factors for progression in HER2 positive MBC do not significantly differ between various distributions of metastases, and that MBC pts benefit from anti-HER2 therapy even in late treatment-lines.

Original languageEnglish
Pages (from-to)530-538
Number of pages9
JournalClinical and Translational Oncology
Volume17
Issue number7
DOIs
Publication statusPublished - Jul 22 2015

Fingerprint

Disease Progression
Breast Neoplasms
Neoplasm Metastasis
Therapeutics
human ERBB2 protein
Proportional Hazards Models
Meta-Analysis
Databases
Hormones
Bone and Bones

Keywords

  • Disease progression
  • HER2 positive metastatic breast cancer
  • Lapatinib
  • Meta-analysis
  • Time to progression
  • Trastuzumab

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Serpico, D., Porcu, L., Tessari, A., Gevorgyan, A., Bregni, G., Galli, G., ... Di Cosimo, S. (2015). Disease progression pattern in metastatic breast cancer patients treated with anti-HER2 therapies. Clinical and Translational Oncology, 17(7), 530-538. https://doi.org/10.1007/s12094-015-1274-2

Disease progression pattern in metastatic breast cancer patients treated with anti-HER2 therapies. / Serpico, D.; Porcu, L.; Tessari, A.; Gevorgyan, A.; Bregni, G.; Galli, G.; de Braud, F.; Torri, V.; Di Cosimo, S.

In: Clinical and Translational Oncology, Vol. 17, No. 7, 22.07.2015, p. 530-538.

Research output: Contribution to journalArticle

Serpico, D. ; Porcu, L. ; Tessari, A. ; Gevorgyan, A. ; Bregni, G. ; Galli, G. ; de Braud, F. ; Torri, V. ; Di Cosimo, S. / Disease progression pattern in metastatic breast cancer patients treated with anti-HER2 therapies. In: Clinical and Translational Oncology. 2015 ; Vol. 17, No. 7. pp. 530-538.
@article{742a30dc8c834ab390a0d36648670a3b,
title = "Disease progression pattern in metastatic breast cancer patients treated with anti-HER2 therapies",
abstract = "Purpose: Over the last decade a dramatic improvement in the treatment and prognosis of human epidermal growth factor receptor-2 (HER2) positive metastatic breast cancer (MBC) has been achieved. This study aimed to describe pattern, timing of metastases, and time to progression (TTP) of MBC patients (pts) treated with multiple lines of therapy with trastuzumab and/or lapatinib. Methods: Clinical-pathologic features, treatment-lines and metastatic sites were collected from the institutional database; TTP was evaluated for each treatment-line. A meta-analysis of treatment-line estimates was performed; Q test and I2-index were used to detect and estimate heterogeneity. Cox’s proportional hazards model and Fine and Gray’s proportional subhazards model in a competing risks setting were used to detect differences in hazard rate and to estimate relative risks. Results: 112 pts were analyzed. The median number of treatment-lines administered was 6 (range 1–17) and 524 (86 {\%}) disease progression events were observed (median follow up 4.2 years). Distribution of metastases at baseline remained consistent across all lines. Having a given site affected by metastasis was a major risk factor of progression in that site. Hormone-receptor-positive pts resulted more likely to progress on bone (HR = 1.88). Elderly pts were less likely to progress on CNS (HR = 0.73). Median TTP resulted superior to 5 months up to the 6th line of treatment, reaching a plateau at the 9th treatment-line. Conclusions: These data suggest that risk factors for progression in HER2 positive MBC do not significantly differ between various distributions of metastases, and that MBC pts benefit from anti-HER2 therapy even in late treatment-lines.",
keywords = "Disease progression, HER2 positive metastatic breast cancer, Lapatinib, Meta-analysis, Time to progression, Trastuzumab",
author = "D. Serpico and L. Porcu and A. Tessari and A. Gevorgyan and G. Bregni and G. Galli and {de Braud}, F. and V. Torri and {Di Cosimo}, S.",
year = "2015",
month = "7",
day = "22",
doi = "10.1007/s12094-015-1274-2",
language = "English",
volume = "17",
pages = "530--538",
journal = "Clinical and Translational Oncology",
issn = "1699-048X",
publisher = "Springer-Verlag Italia",
number = "7",

}

TY - JOUR

T1 - Disease progression pattern in metastatic breast cancer patients treated with anti-HER2 therapies

AU - Serpico, D.

AU - Porcu, L.

AU - Tessari, A.

AU - Gevorgyan, A.

AU - Bregni, G.

AU - Galli, G.

AU - de Braud, F.

AU - Torri, V.

AU - Di Cosimo, S.

PY - 2015/7/22

Y1 - 2015/7/22

N2 - Purpose: Over the last decade a dramatic improvement in the treatment and prognosis of human epidermal growth factor receptor-2 (HER2) positive metastatic breast cancer (MBC) has been achieved. This study aimed to describe pattern, timing of metastases, and time to progression (TTP) of MBC patients (pts) treated with multiple lines of therapy with trastuzumab and/or lapatinib. Methods: Clinical-pathologic features, treatment-lines and metastatic sites were collected from the institutional database; TTP was evaluated for each treatment-line. A meta-analysis of treatment-line estimates was performed; Q test and I2-index were used to detect and estimate heterogeneity. Cox’s proportional hazards model and Fine and Gray’s proportional subhazards model in a competing risks setting were used to detect differences in hazard rate and to estimate relative risks. Results: 112 pts were analyzed. The median number of treatment-lines administered was 6 (range 1–17) and 524 (86 %) disease progression events were observed (median follow up 4.2 years). Distribution of metastases at baseline remained consistent across all lines. Having a given site affected by metastasis was a major risk factor of progression in that site. Hormone-receptor-positive pts resulted more likely to progress on bone (HR = 1.88). Elderly pts were less likely to progress on CNS (HR = 0.73). Median TTP resulted superior to 5 months up to the 6th line of treatment, reaching a plateau at the 9th treatment-line. Conclusions: These data suggest that risk factors for progression in HER2 positive MBC do not significantly differ between various distributions of metastases, and that MBC pts benefit from anti-HER2 therapy even in late treatment-lines.

AB - Purpose: Over the last decade a dramatic improvement in the treatment and prognosis of human epidermal growth factor receptor-2 (HER2) positive metastatic breast cancer (MBC) has been achieved. This study aimed to describe pattern, timing of metastases, and time to progression (TTP) of MBC patients (pts) treated with multiple lines of therapy with trastuzumab and/or lapatinib. Methods: Clinical-pathologic features, treatment-lines and metastatic sites were collected from the institutional database; TTP was evaluated for each treatment-line. A meta-analysis of treatment-line estimates was performed; Q test and I2-index were used to detect and estimate heterogeneity. Cox’s proportional hazards model and Fine and Gray’s proportional subhazards model in a competing risks setting were used to detect differences in hazard rate and to estimate relative risks. Results: 112 pts were analyzed. The median number of treatment-lines administered was 6 (range 1–17) and 524 (86 %) disease progression events were observed (median follow up 4.2 years). Distribution of metastases at baseline remained consistent across all lines. Having a given site affected by metastasis was a major risk factor of progression in that site. Hormone-receptor-positive pts resulted more likely to progress on bone (HR = 1.88). Elderly pts were less likely to progress on CNS (HR = 0.73). Median TTP resulted superior to 5 months up to the 6th line of treatment, reaching a plateau at the 9th treatment-line. Conclusions: These data suggest that risk factors for progression in HER2 positive MBC do not significantly differ between various distributions of metastases, and that MBC pts benefit from anti-HER2 therapy even in late treatment-lines.

KW - Disease progression

KW - HER2 positive metastatic breast cancer

KW - Lapatinib

KW - Meta-analysis

KW - Time to progression

KW - Trastuzumab

UR - http://www.scopus.com/inward/record.url?scp=84937628907&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84937628907&partnerID=8YFLogxK

U2 - 10.1007/s12094-015-1274-2

DO - 10.1007/s12094-015-1274-2

M3 - Article

C2 - 25604128

AN - SCOPUS:84937628907

VL - 17

SP - 530

EP - 538

JO - Clinical and Translational Oncology

JF - Clinical and Translational Oncology

SN - 1699-048X

IS - 7

ER -